Coming Soon!

Comprehensive panel

We test for 125 genes that change the way your body metabolizes medications. Over 100 medications currently have FDA clinical advisories for gene – drug interaction. Your genes may cause you to be an ultra-rapid metabolizer, rapid metabolizer, normal responder, poor metabolizer or a non-responder. You may be in danger of adverse reactions or the medication may not work at all. With our comprehensive panel you will have the most complete evaluation of your response to medications.

Cardiac pharmacogenomics panel

We test for 67 genes that target gene variants that interact with cardiac medication metabolism. Included in this panel are interactions with clopidogrel, warfarin, beta blockers, ACE inhibitors, ARBs, calcium channel blockers, statin medication and many more.

Pain pharmacogenomic panel

We test for 19 genes that have a role in drug metabolism with medications for pain. It is now well known that certain variants change the metabolism of codeine, tramadol, hydrocodone and oxycodone to their active metabolites. There are other genes that interact with non-steroidal anti-inflammatory agents like ibuprofen and others in the same category. There are metabolic actions that affect acetaminophen. Some gene variants can cause an increase in adverse reactions while others can interfere with pain control.

Psychiatry pharmacogenomic panel

We test for 35 genes that have the potential to change the way medication is metabolized that specifically affects medications for Alzheimers, ADHD, epilepsy, depression, anxiety and other diseases and disorders that concern thought and behavior.